P21 is not a prognostic marker for rectal cancer – five-year follow up study of rectal cancer in stages I–IV

Kozłowska-Geller, Monika; Głuszek, Stanisław; Lewitowicz, Piotr

doi:10.5114/wo.2020.102632

Cited by 1 publication

(3 citation statements)

References 33 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A very close connection of p21 with TP53 suppressor gene mutation led to the conclusion about its clinical usefulness in outcome prognosis. In assessing the clinical value of p21, the nuclear accumulation of this protein was usually determined qualitatively, with its presence in tumor cells between 36% and 71%, and even up to 80% of cases [ 32 , 33 ].…”

Section: Discussionmentioning

confidence: 99%

“…Observation of the course of treatment for relapse covered the period up to 102 months after surgery. In the literature, there was no clear relationship between the development of tumor recurrence and the appearance of p21ras protein expression [ 33 , 34 ]. In our study, it was also found that the level of p21 did not affect cancer recurrence.…”

Section: Discussionmentioning

confidence: 99%

“…This conclusion was confirmed by our study, as there were no statistically significant differences in RFS between groups of patients in expression groups 0, 1, 2, 3, p -value = 0.9650 in the log-rank test. Based on the data presented, we suggest a lack of prognostic significance of p21 in patients with sporadic rectal adenocarcinoma; however, the immunohistochemical assessment of the presence of p21ras may be useful in assessing tumor biology, especially in combination with other molecular preparations [ 33 , 36 , 37 ].…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Five-year follow-up study of stage I-IV rectal cancer including EGFR immunoexpression and p21 immunoactivity

Kozłowska-Geller¹,

Głuszek²,

Lewitowicz³

2021

Self Cite

View full text Add to dashboard Cite

Introduction: Both environmental and genetic factors increase the likelihood of developing rectal cancer. Aim: To assess the EGFR and p21 immunoreactivity in rectal cancer and to assess its relationship with the clinical outcome. Material and methods: Applying exclusion criteria, 102 patients with stage I-IV rectal cancer, who had undergone scheduled surgery during the period 2005-2011, were included in the study. There was a follow-up study with a span of 5 years from the date of the surgery. Immunohistochemistry using epidermal growth factor receptor (EGFR Ab10, Clone111.6) and antibodies against p21 (p21 WAF1 (Clone H252)) was performed to detect overexpression of the targeted receptor. Digital analysis of positive reactions of membranes and nuclei was performed utilizing Visiopharm.Results: The degree of EGFR intensity (log OR = 0.854, OR = 2.35, 95% CI: 1.14-4.85, p = 0.021) is a significant factor in the prognosis of death within 2 years after surgery. The OS curve showed a significant decrease after 40 months from the date of surgery in the cases where EGFR had high expression. The ROC curve for cancer stage, according to the UICC classification and EGFR expression, in order to predict 2-year RFS, reached a high specificity value (ROC = 0.81, p = 0.0408). The analysis showed no statistically significant differences in the survival curves of patients in groups with immunoreactivity of p21 protein at 0, 1, 2, 3 (p = 0.6453 in the log-rank test). Also, it is not a significant risk factor for death (HR = 0.915, p = 0.7842) or for tumor dissemination (HR = 0.94, p = 0.9426).Conclusions: The determination of EGFR immunoreactivity is important in the monitoring and treatment of patients with rectal cancer, as opposed to p21.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%